Another Failed Product – What Will GSK Do Now?

With GlaxoSmithKline’s megablockbuster Advair soon to be experiencing fierce generic competition, investors were assured that the pharma giant had another remedy in hand. Excitement built around Breo Ellipta, a drug developed to improve the mortality rate of high-risk patients with COPD, but the product hasn’t exactly played out as planned. Will the company be able to survive with its recent R&D track record? Read more here. (Source: John Carrol, FierceBiotech, 9/8/15)